ArticleBMJ open ophthalmology2025

Anti-VEGF treatment switch in real-world DME patients: ranibizumab versus aflibercept for bevacizumab DME non-responding patients (SWIRL study).

Louis W Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.